000121612 001__ 121612 000121612 005__ 20241125101128.0 000121612 0247_ $$2doi$$a10.3390/cancers15030721 000121612 0248_ $$2sideral$$a132184 000121612 037__ $$aART-2023-132184 000121612 041__ $$aeng 000121612 100__ $$aHijos-Mallada, Gonzalo$$uUniversidad de Zaragoza 000121612 245__ $$aA Point-of-Care Faecal Test Combining Four Biomarkers Allows Avoidance of Normal Colonoscopies and Prioritizes Symptomatic Patients with a High Risk of Colorectal Cancer 000121612 260__ $$c2023 000121612 5060_ $$aAccess copy available to the general public$$fUnrestricted 000121612 5203_ $$aMost colonoscopies performed to evaluate gastrointestinal symptoms detect only non-relevant pathologies. We aimed to evaluate the diagnostic accuracy of a qualitative point-of-care (POC) test combining four biomarkers (haemoglobin, transferrin, calprotectin, and lactoferrin), a quantitative faecal immunochemical test (FIT) for haemoglobin, and a quantitative faecal calprotectin (FC) test in symptomatic patients prospectively recruited. Colorectal cancer (CRC), adenoma requiring surveillance, inflammatory bowel disease (IBD), microscopic colitis, and angiodysplasia were considered significant pathologies. A total of 571 patients were included. Significant pathology was diagnosed in 118 (20.7%), including 30 CRC cases (5.3%). The POC test yielded the highest negative predictive values: 94.8% for a significant pathology and 100% for CRC or IBD if the four markers turned negative (36.8% of the patients). Negative predictive values of FIT, FC, and its combination for diagnosis of a significant pathology were 88.4%, 87.6%, and 90.8%, respectively. Moreover, the positive predictive value using the POC test was 82.3% for significant pathology when all biomarkers tested positive (6% of the patients), with 70.6% of these patients diagnosed with CRC or IBD. The AUC of the POC test was 0.801 (95%CI 0.754-0.848) for the diagnosis of a significant pathology. Therefore, this POC faecal test allows the avoidance of unnecessary colonoscopies and prioritizes high risk symptomatic patients. 000121612 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000121612 590__ $$a4.5$$b2023 000121612 592__ $$a1.391$$b2023 000121612 591__ $$aONCOLOGY$$b78 / 322 = 0.242$$c2023$$dQ1$$eT1 000121612 593__ $$aOncology$$c2023$$dQ1 000121612 593__ $$aCancer Research$$c2023$$dQ2 000121612 594__ $$a8.0$$b2023 000121612 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000121612 700__ $$aSaura, Nuria 000121612 700__ $$aLué, Alberto$$uUniversidad de Zaragoza 000121612 700__ $$aVelamazan, Raúl 000121612 700__ $$aNieto, Rocío 000121612 700__ $$aNavarro, Mercedes 000121612 700__ $$aArechavaleta, Samantha 000121612 700__ $$aChueca, Eduardo 000121612 700__ $$0(orcid)0000-0003-0076-3529$$aGomollon, Fernando$$uUniversidad de Zaragoza 000121612 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Angel$$uUniversidad de Zaragoza 000121612 700__ $$aSostres, Carlos 000121612 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina 000121612 773__ $$g15, 3 (2023), 721 [14 pp.]$$pCancers$$tCancers$$x2072-6694 000121612 8564_ $$s880641$$uhttps://zaguan.unizar.es/record/121612/files/texto_completo.pdf$$yVersión publicada 000121612 8564_ $$s2664641$$uhttps://zaguan.unizar.es/record/121612/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000121612 909CO $$ooai:zaguan.unizar.es:121612$$particulos$$pdriver 000121612 951__ $$a2024-11-22-11:58:15 000121612 980__ $$aARTICLE